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Abstract
Meniere’s disease is an inner ear disorder
characterized by the presence of endolymphatic
hydrops in the inner ear and symptomatology of
recurrent and debilitating vertigo attacks, tinnitus,
aural fullness, and fluctuating sensorineural hearing
loss. Although many therapeutic options for MD have
been proposed during years, no consensus has been
reached by the scientific community. In the last
decade, many therapeutic options have been
proposed, as intratympanic steroid, intratympanic
gentamicin, and intravenous glycerol. Recently, the
role of the antisecretory factor in the diet of MD
patients have been investigated. Surgery is
recommended for intractable MD; some authors
proposed new approaches including transcanal
endoscopic infracochlear vestibular neurectomy, new
marsupiliazation technique in sac surgery, and
tenotomy of the stapedius and tensor tympani
muscles.
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I. INTRODUCTION
Meniere disease (MD) is an inner ear disorder
characterized by the presence of endolymphatic hydrops

(EH) in the inner ear and symptomatology of recurrent and
debilitating vertigo attacks, tinnitus, aural fullness, and
fluctuating sensorineural hearing loss (SNHL)1,2,3.
Although hearing loss is mainly sensorineural, lowfrequency air-bone gap (ABG) can also be found in the
absence of middle ear pathology4, mimicking other
conditions such as cerebral vascular anomalies including
dural arteriovenous fistula5. MD symptoms can severely
affect the quality of life6,7.
Although many therapeutic options for MD have been
proposed, no consensus has been reached by the scientific
community8-11. First-line treatment includes dietary
restrictions for salt, caffeine, and alcohol associated to
drugs both for acute attacks (dimenhydrinate,
benzodiazepines)12, and as prophylactic therapy
(betahistine, β-blockers, diuretics)13.
When first-line treatment does not offer satisfactory
symptom control, intratympanic (IT) administration of
gentamicin or corticosteroids can be performed 14; however,
many studies showed that IT gentamicin may expose the
patients to a risk of hearing loss, depending on dosage and
intervals between administrations15. Labyrinthectomy or
other surgical procedures can be suggested for intractable
MD16.
Despite the recent COVID-19 pandemic17-20, scientific
research for MD is a growing area in continuous
development. This brief review aims to assess the clinical
innovations for the therapy of MD.

II. DISCUSSION

Pharmacological Innovations

The main goal of the pharmacological treatment of MD is
to reduce the duration and frequency of vertigo attacks, and
to prevent hearing loss, which is usually progressive.
There’s lack of high-level evidences for efficacy of MD
treatment; for this reason, different drugs and different
methods of administration have being tested.
IT steroids (dexamethasone, methylprednisolone)
treatments have been widely used for MD, especially when
first-line treatment does not offer a satisfactory symptoms
control; however, there is still lack of evidence that this
treatment may have a positive effect in MD 21. Pradhan et
al22 evaluated the effects of IT dexamethasone in 30
patients with refractory MD comparing the pre- and posttreatment hearing outcome and dizziness score. They found
that 23% of patients were free of vertigo at the end of 24
months after IT steroids, but there was no significant
improvement in hearing. These results are in accordance
with those from Weckel et al23 who retrospectively
evaluated 25 patients treated with IT dexamethasone; they
reported a satisfactory control of vertigo in 92% of the
patients, and this protocol achieved control of vertigo in
70% of patients at 2 years. Harcourt et al 24 suggested IT
methylprednisolone as an effective treatment for the longterm control of vertigo attacks, without he known inner-ear
toxicity associated with gentamicin.
Gentamicin, administered at different doses and timing 25,
has been proven as an effective treatment for vertigo
control in MD with a potential risk of herring loss;
however, discussion about the dosage and the method used
is open26. Scarpa et al27 proposed a low-dose IT gentamicin
protocol; they treated 48 patients with 0.5 ml of 10 mg of
gentamicin with an interval of 2 weeks between injections.
They reported a satisfactory control of vertigo attacks after
IT gentamicin, and the effect of this protocol on vestibular
system was proved by the reduction in vestibulo-ocular
reflex (VOR) gain in the affected side. A meta-analysis
from Jian et al28 demonstrated that IT gentamicin is
superior to IT steroids in reducing the number of vertigo
attacks, but both drugs didn’t show hearing improvement.
Moreover, Ozturk and Ata proposed an IT mixture of
gentamicin and dexamethasone injection for the treatment
of intractable MD, even more effective that IT
dexamethasone for vertigo control29.
Diuretics have also been recommended to control vertigo
attacks in MD, due to their effects in reducing the
endolymphatic pressure and volume. As for steroids and
gentamicin, there are no high-quality data demonstrating
the efficacy of oral diuretic therapy 30; in addition, a metaanalysis from Rosenbaum and Winter31 concluded that it is
not clear if diuretic lead to a symptomatic improvement of
vertigo.
A prospective study from Scarpa et al32 evaluated the
effectiveness on vertigo control of intravenous (IV)
glycerol (an osmotic diuretic), 10% glycerol with 0.9%
sodium chloride, 0.5 g/kg once a day for 2 consecutive days
every fifteen days for six months; the authors reported an
improvement of vertigo attacks and a significant reduction
of discomfort generated by tinnitus, raising quality of life.

Recently, some authors suggested a possible action of antisecretory factor (AF), a protein produced by pituitary gland
that plays a role in the innate defense against the
inflammatory and secretory components of diarrheal
disease33. It has been hypothesized that AF can act as a
modulator of water and ions and interact with the
aquaporins. Viola et al34 observed a significant
improvement in daily activities in patients treated with
specially processed cereals (SPC) compared to those
treated with IV glycerol and dexamethasone. The study
reported a significant reduction of vertigo spells and a
positive effect on tinnitus severity.
Surgical Innovations
According to international guidelines, surgical therapy for
MD is recommended only for refractory disease, and
therefore represents the third (or even the fifth) line of
management. Currently, the most popular surgical
procedures to control vertigo attacks in MD are also the
most aggressive and those that have the most negative
impact on auditory function. Besides, there is a lack of
evidence suggesting that surgical therapy for MD may
provide a significant control of symptoms35.
The table below shows the main surgical procedures for
MD taking into account of hearing preservation, vestibular
injury, surgical difficulty and long-term outcomes (Table
1).

Endolymphatic sac surgery (ESS) can be considered in
patients that are refractory to medical management as a
nondestructive option, as the risk to damage hearing is
low36. Xu et al37 suggested that ESS with posterior
tympanotomy and local steroid treatment could improve
hearing and ensure a satisfactory vertigo control in patients
with intractable MD. In Gibson et al opinion 38, ESS can

provide a vertigo control at least as well as IT gentamicin
with a lower incidence of audio-vestibular complications39.
Transmastoid labyrinthectomy alone40 or in combination
with cochlear implantation41, grommet insertion42, and
triple semicircular canal plugging43 have been proposed as
an effective surgical option for the treatment of MD.
New techniques have been recently described. Daneshi et
al44 evaluated the results of a new marsupialization
technique in endolymphatic sac decompression surgery, in
which the outer layer of the sac was turned around and
placed under the anterior bony border. They concluded that
this technique can control progressive hearing loss and
improve tinnitus, vertigo, and ear fullness among patients
with intractable unilateral MD.
Moreover, Trakimas et al45 proposed a transcanal
endoscopic infracochlear vestibular neurectomy on cadaver
as a minimally invasive approach to distal vestibular
neurectomy.
More recently, some authors suggested that tenotomy of the
stapedius and tensor tympani muscles (TSTM) may be a
safe surgical procedure with significant vertigo control,
decreased postoperative symptoms and important hearing
preservation46.
Diagnostic Innovations
In the diagnosis and the evaluation of therapy efficacy, the
audio-vestibular test battery has a primary role, and the
diagnostic findings are constantly evolving.
Di Stadio et al proposed head-shaking nystagmus (HSNy)
as a useful test in the early stages of MD to predict a new
vertigo attack, with a sensitivity of the ipsilesional HSNy
of 100% at T0 and 85.7% at T147.
Lee SU et al48 evaluated the VOR performance during the
attacks of MD using video head-impulse tests (video-HITs)
according to each ictal phase; the authros suggested that
during the vertigo attack, HITs are normal during irritative
and recovery phases, but abnormal in 53% of the patients
during the paretic phase, reflecting characteristic ictal
vestibular discharges. Besides, a common finding in MD is
a normal horizontal HIT with an asymmetric caloric
function, and this dissociation can be used as a diagnostic
marker49.
Patients with suspected MD can be examined using
magnetic resonance imaging (MRI) to evaluate a possible
inner ear disease. The MRI findings in patients with MD
are conflicting, due to the MRI sequences used and the
inclusion criteria of the patients; also, the early stage of MD
and the early symptoms appear too subtle for identification
using MRI, making the reproducibility of hydrops MRI
scan protocols debatable50.

III. CONCLUSION
Despite accumulating evidence for the treatment
of MD, there is currently no international consensus on a
standardized therapeutic protocol for this condition.

Intravenous administration of glycerol, low-dose
intratympanic gentamicin, and antisecretory factor are
promising innovations.
The role of surgery in the treatment of MD is still debated;
recent techniques as tenotomy of the stapedius and tensor
tympani muscles seems to offer interesting insights, but
larger randomized studies are needed to draw conclusions.
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